In our latest podcast, Lonza Capsugel’s Frank Romanski explores how patient preference is reshaping development strategies. Oral delivery is not just a scientific ambition. It is a route to expanding total addressable market and reaching patients who would otherwise go untreated.
Companies are investing heavily in oral biologics because access drives impact. Even with formulation losses, the opportunity to treat more people is compelling.
Listen to the full conversation to understand why oral delivery has become such a strategic priority.
* The presented information was correct and current at the time of publication.
Latest CHI content